Company Encyclopedia
View More
name
CARDIOFLOW-B
02160.HK
MicroPort CardioFlow Medtech Corporation, a medical device company, engages in the research, development, and commercialization of transcatheter and surgical solutions for structural heart diseases in the People’s Republic of China and internationally. The company engages in research and development, manufacture, and sale of medical devices in the field of left atrial appendage, and treating valvular heart diseases, as well as properties management. It’s product portfolio includes transcatheter aortic valves, left atrial appendage closure, transcatheter mitral valves, transcatheter tricuspid valves, and surgical accessories, as well as procedural accessories; and VitaFlow, VitaFlow Liberty, VitaFlow Liberty Flex, Alwide Plus, AccuSniperTM, AnchorMan LAAC System, AnchorMan LAAA System, and various TAVI, TMV, TTV, and LAA products. In addition, the company provides technical consultation and technical services for medical devices clinical trial.
132.25 B
02160.HKMarket value -Rank by Market Cap -/-

Financial Score

21/11/2025 Update
C
Health Care EquipmentIndustry
Industry Ranking17/26
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE0.22%D
    • Profit Margin1.32%C
    • Gross Margin70.24%A
  • Growth ScoreC
    • Revenue YoY-3.87%D
    • Net Profit YoY101.39%A
    • Total Assets YoY8.80%B
    • Net Assets YoY2.76%C
  • Cash ScoreB
    • Cash Flow Margin7574.81%A
    • OCF YoY-3.87%D
  • Operating ScoreE
    • Turnover0.14E
  • Debt ScoreA
    • Gearing Ratio16.89%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    CARDIOFLOW-B, merged subsidiaries, and MicroPort Cardiac Rhythm Management have entered into a merger agreement for the transaction

    CARDIOFLOW-B announced a merger agreement with MicroPort Cardiac Rhythm Management, planning to complete it by September 29, 2025. According to the agreement, CARDIOFLOW will acquire MicroPort Cardiac Rhythm Management through a merger, and the latter will become its indirect wholly-owned subsidiary. The target company is valued at USD 680 million, aiming to enhance CARDIOFLOW's global influence in the cardiovascular product field and achieve business synergies

    Zhitong·
    HK
    02160
    -4.39%
    Zhitong·
    HK
    02160
    -4.39%

    CARDIOFLOW-B released its interim results, with a loss attributable to shareholders of RMB 2.163 million, a year-on-year decrease of 96.17%

    CARDIOFLOW-B released its interim results for the period ending June 30, 2025, with revenue of 229 million yuan, an increase of 2.67% year-on-year. The loss attributable to shareholders was 2.163 million yuan, a decrease of 96.17% year-on-year, with a basic loss per share of 0.09 yuan. The revenue growth was mainly driven by the global commercialization of the VitaFlow Liberty® transcatheter aortic valve and its retrievable delivery system, as well as the steady progress of the AnchorMan® left atrial appendage occlusion system and guiding system in both domestic and international markets

    Zhitong·
    HK
    02160
    -4.39%
    Zhitong·
    HK
    02160
    -4.39%

    Understanding the Market | CARDIOFLOW-B fell nearly 7% before earnings, will release mid-term results after today's trading session, previously expected to narrow losses by up to 83% in the first half of the year

    CARDIOFLOW-B fell nearly 7% before earnings, and as of the time of publication, it was down 4.2%, trading at HKD 1.37, with a transaction volume of HKD 11.3101 million. In terms of news, CARDIOFLOW plans to hold a board meeting on August 28 to approve its interim results. The company previously issued a profit warning, expecting a net loss of no more than RMB 10 million in the first half of 2025, a year-on-year decrease of no less than 83%. The announcement stated that the reduction in net loss was mainly due to the sales of the VitaFlow Liberty transcatheter aortic valve and its retrievable delivery system in more than 20 countries/regions overseas, with overseas revenue increasing more than twofold; the commercialization progress of the AnchorMan left atrial appendage occluder system and its guiding system in China is steadily advancing, and it has obtained CE marking for commercialization in Europe, contributing to revenue growth; continuous optimization of resource allocation and other measures have further improved operational efficiency; and the joint venture 4C Medical completed Series D financing, resulting in a decrease in the group's shareholding, which is considered as gains from the sale of equity

    Zhitong·
    HK
    02160
    -4.39%
    Zhitong·
    HK
    02160
    -4.39%

    CARDIOFLOW-B: Alwide® Plus cardiac valve balloon dilation catheter has obtained CE mark approval

    CARDIOFLOW-B announced that its Alwide® Plus cardiac valve balloon dilation catheter has received CE mark approval, meeting European health, safety, and environmental standards. This product is used for pre-dilation of calcified aortic valves in transcatheter aortic valve implantation (TAVI), featuring ultra-low compliance, high burst pressure, rapid filling, and excellent puncture resistance, reducing surgical risks. This approval will facilitate the commercialization of products such as VitaFlow Liberty® in Europe, further advancing the company's overseas strategy

    Zhitong·
    HK
    02160
    -4.39%
    Zhitong·
    HK
    02160
    -4.39%

    Understanding the Market | CARDIOFLOW-B rose over 4% in the morning and is expected to release its performance at the end of this month, with a projected net loss in the first half of the year decreasing by no less than 83% year-on-year

    CARDIOFLOW-B's stock price rose more than 4% in the morning, reaching HKD 1.54, with a transaction volume of HKD 16.2265 million. The company expects a net loss of no more than RMB 10 million in the first half of 2025, a year-on-year decrease of no less than 83%. The main reasons include the growth in overseas sales of the VitaFlow Liberty® product, the commercialization progress of the AnchorMan® system in China, resource allocation optimization, and gains from equity sales. The board of directors will hold a meeting on August 28 to review the interim performance

    Zhitong·
    HK
    02160
    -4.39%
    Zhitong·
    HK
    02160
    -4.39%